Introduction {#S1}
============

Ferroptosis is a type of regulated cell death dependent on iron. In 2012, ferroptosis was first used to describe cell death induced by erastin, a small molecule that inhibits cystine uptake and leads to reduced glutathione (GSH) production, as well as the inactivation of glutathione peroxidase 4 (GPX4) ([@B13]). Ferroptosis relies on intracellular iron rather than other metallic elements and could be inhibited by iron chelators and antioxidants, such as vitamin E. Moreover, it is distinct from other forms of cell death, including apoptosis, necroptosis, and autophagy-dependent cell death, in terms of morphology, biochemistry, and genetics ([@B13]). Furthermore, inhibitors of apoptosis, necroptosis, or autophagy are incapable of suppressing ferroptosis ([@B18]).

The main characteristic of ferroptosis is death due to the accumulation of lethal levels of iron-dependent lipid peroxides (for review, see [@B51]). Previous studies have shown that ferroptosis has pathological roles in a wide variety of diseases, including neurodegenerative diseases, cancer, ischemia--reperfusion injury, stroke, and traumatic brain injury (for review, see [@B9]; [@B53]; [@B45]; [@B67]; [@B77]).

Distinct Morphological Features of Ferroptosis as Compared to Apoptosis, Necrosis, and Autophagy {#S2}
================================================================================================

Morphologically, ferroptotic cells exhibit typical features of necrosis, with no apoptosis features. Importantly, ferroptosis is accompanied by a series of morphological changes in the mitochondria, including cristae reduction, membrane coagulation, and rupture of the outer membrane, whereas in other forms of cell death, the mitochondria are usually swollen ([@B13]). Moreover, in cancer cells treated with ferroptosis inducers, like erastin, the structural integrity of the nucleus is maintained, with no nucleation or chromatin edge observed. These differences in morphological features are important to distinguish ferroptosis from apoptosis, necrosis, and autophagy ([@B69]).

Biochemical processes related to ferroptosis include metabolisms involving iron, amino acids, or polyunsaturated fatty acids (PUFAs), as well as the biosynthesis of GSH, phospholipids, and nicotinamide adenine dinucleotide phosphate, and coenzyme Q~10~ (for review, see [@B63]).

Iron, Amino Acid, and Lipid Metabolisms Are Deeply Involved in the Molecular Mechanisms of Ferroptosis {#S3}
======================================================================================================

Notably, mechanisms associated with ferroptosis are complex and mainly include three factors: iron, amino acid, and lipid metabolisms. Iron is an essential element in ferroptosis. A robust increase in iron levels can trigger the accumulation of lipid peroxides and reactive oxygen species (ROS), resulting in ferroptosis ([@B71]).

Amino acid metabolism is closely associated with ferroptosis. In most cases, the intake of cysteine occurs via cystine/glutamate reverse transporters (system xc-), which function in the intracellular environment to synthesize GSH and maintain the antioxidant activity of GPX4.

Lipoxygenase transforms esterified PUFAs located in the cell membrane into lipid peroxides ([@B72]). Reportedly, lipoxygenase is a crucial agent playing a direct role in ferroptosis ([@B72]). Coenzyme Q~10~, a downstream effector of β-hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase, which synthesizes mevalonic acid (MVA), is an endogenous ferroptosis inhibitor possessing profound antioxidant effects in the intracellular environment ([@B60]). Suppression of this coenzyme can potentiate the accumulation of lipid peroxides, resulting in cell death ([@B60]). According to the latest research, *FSP1* represses lipid peroxidation by reducing coenzyme Q~10~ through NAD(P)H, thus eliciting an inverse role in the occurrence of ferroptosis ([@B3]; [@B16]). These results indicate that in ferroptosis, cell death is characterized by lipid peroxidation. Conceivably, the interventions of ferroptosis by targeting lipid peroxidation are reasonable.

Iron Metabolism {#S3.SS1}
---------------

Iron overload is a key event in ferroptosis, with Fe^2+^ generating lipid ROS through the Fenton reaction (for review, see [@B67]). Furthermore, Fe^2+^ constitutes the lipoxygenase (LOX) catalytic subunit that initiates lipid peroxidation. Both these functions of Fe^2+^ are crucial for the onset of ferroptosis. There are two transport mechanisms for the entry of non-heme iron into cells: transferrin (TF)-dependent and TF-independent mechanisms. Several mechanisms occur independently of TF; for example, extracellular Fe^2+^ enters cells through membrane divalent metal transporter 1 (DMT1). However, most plasma Fe^3+^ exists in the complete form with TF and is transformed into holotransferrin (for review, see [@B27]). After endocytosis, holotransferrin binds to TF receptor 1 (TFR1) on the cell membrane surface and subsequently moves to endosomes. In the acidic environment of the endosome, Fe^3+^ is released from TF and converted into Fe^2+^ through oxidation--reduction. Consequently, Fe^2+^ is transported to the labile iron pool in the cytoplasm through DMT1 on the endosome membrane, where it forms a complex that functions as a physiological or pathological element (for review, see [@B56]; [@B27]). The secretion or storage of excessive Fe^2+^ in the ferritin complex blocks the formation of hydroxyl radicals from H~2~O~2~, thus preventing ROS production (for review, see [@B56]). Some Fe^2+^ ions are transported outside the cell membrane through ferroportin1 (FPN1) residing in the cell membrane; therefore, the intracellular iron concentration is considered appropriate under physiological conditions ([@B19]).

Amino Acid Metabolism {#S3.SS2}
---------------------

A study has shown that the entrance of cystine into the cytoplasm could be the mainstay of ferroptotic suppression, through the maintenance of intracellular GSH levels ([@B40]). In contrast, the decrease in GSH synthesis contributes to ferroptosis ([@B55]). The translocation of extracellular cystine and intracellular glutamate by system xc- is driven by the high glutamate concentration in the intracellular environment, rather than ATP, at a ratio of 1:1, and the repression of system xc- directly results in ferroptosis ([@B13]). Following the injury of brain tissue, system xc- is impacted by the high concentration of extracellular glutamate ([@B32]; for review, see [@B4]). After crossing the cytomembrane, cystine is degraded into cysteine and, subsequently, cysteine is converted into γ-glutamyl-cysteine by glutamyl-cysteine ligase. Then, γ-glutamyl-cysteine combines with glycine to form GSH, which in turn is activated by glutathione synthase (for review, see [@B2]).

In recent years, the suppression of GPX4, a key anti-lipid peroxidation enzyme, has been considered a committed step of ferroptosis, either through a direct (such as via covalent inhibition of RSL3 and its related molecules; [@B73]) or indirect (such as via GSH depletion) manner, provoking the unacceptable upregulation of phospholipid--OH and alkyl oxygen free radicals, causing severe membrane damage and ferroptosis ([@B13]; [@B71]). GPX4 activates phospholipid--OH to phospholipid-H via a reduction reaction, with the consumption of two molecules of GSH ([@B71]). Additionally, GSH is transformed into oxidized glutathione ([@B71]). Oxidized glutathione is then reduced to GSH by the nicotinamide adenine dinucleotide phosphate-dependent glutathione reductase, entering the next cycle of reduction reaction ([@B43]). The oxidized phospholipid--OH is converted into massive alkyl oxygen free radicals with highly reactivity initiated by intracellular free Fe^2+^ (for review, see [@B21]). The latter induces adverse effects on adjacent PUFAs through a cascade of chain reactions. Eventually, an extensive spectrum of membrane damage occurs, decreasing cell viability and even causing death (for view see [@B55]).

Furthermore, as a binding ligand for free Fe^2+^ in the labile iron pool, GSH can prevent Fe^2+^ from reacting with H~2~O~2~. Conversely, highly cytotoxic hydroxyl radicals are generated by the lack of GSH (for review see [@B55]).

Lipid Metabolism {#S3.SS3}
----------------

Lipid metabolism is closely related to ferroptosis (for review, see [@B63]). Considering that PUFAs are sensitive to oxidants, they function as primary substrates of lipid peroxidation related to ferroptosis, especially arachidonic acid (AA) and adrenic acid (AdA) ([@B71]). First, PUFAs are esterified with membrane phospholipids, mainly phosphatidylethanolamine (PE). The esterification reaction is catalyzed by acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3), resulting in the formation of AA/AdA-PE. Next, LOX converts PE-AA/AdA into PE-AA/AdA-OH through oxidation, thereby inducing ferroptosis ([@B14]; [@B72]; [@B17]; [@B33]; [@B61]). Furthermore, the degree of ferroptosis can be determined by measuring the amount of peroxidized PUFAs and examining their subcellular localization ([@B63]). However, the specific mechanism through which lipid peroxidation mediates ferroptosis remains unknown ([@B20]).

Ferroptosis Exerts Profound Regulatory Effects in Cerebral Ischemic Brain Injury {#S4}
================================================================================

The relationship between ferroptosis, as a fundamental form of cell death in the nervous system, and neurological diseases has been reported in several diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, traumatic brain injury, and periventricular leukomalacia ([@B7]; [@B15]; [@B22]; for review, see [@B62]; [@B25]; [@B26]; [@B45]; [@B77]).

Ischemic stroke (IS) is a major cause of death and disability worldwide. It is characterized by the sudden obstruction of local blood flow to the brain and results in irreversible damage and deficiency of nerve function (for review, see [@B41]). There are multiple mechanisms involved in ischemic neuronal injury, among which oxidative stress is important in the progression of ischemic injury. In ischemic brain tissue, the defense ability of the antioxidant system is weakened owing to ROS elevation, followed by the excessive production of oxygen free radicals, deactivation of antioxidant enzymes, and antioxidant depletion. This results in multiple deleterious events, including peroxidation of lipids and proteins, damage to nuclear DNA, and cell death (for review, see [@B5]). Moreover, it has been shown that oxidative damage in the ischemic brain tissue is continuous and even spreads to surrounding healthy tissues; however, treatment with antioxidants can noticeably attenuate cerebral ischemic damage ([@B31]). A recent study has reported that oxidative stress injury can induce ferroptosis and leads to neuronal death in neurodegenerative diseases ([@B8]) and that BID plays an important role in the ferroptosis mechanism-induced oxidative stress ([@B52]) and is hence possibly linked with cerebral ischemic damage. However, the role of ferroptosis remains unclear in cerebral ischemia and further research is needed. Multiple studies have revealed that ferroptosis plays a regulatory role in ischemic brain damage, mainly in neurons. However, the suppressive intervention of ferroptosis can exert neuroprotective effects ([@B10]). These findings imply that ferroptosis possesses the potential to serve as a therapeutic target for cerebral ischemia ([@B6]; [@B24]; [@B68]; [@B75]).

Reportedly, ferroptosis exerts profound regulatory effects during ischemia--reperfusion brain injury. Additionally, ferroptosis has been detected in mouse models of cerebral ischemia. Administration of the ferroptosis inhibitors, liproxstatin-1 or ferrostatin-1 (Fer-1), after reperfusion, generated a markedly smaller infarct, thus alleviating cerebral injury ([@B68]). Furthermore, studies have revealed that inhibition of ferroptosis can reduce ischemic brain damage in rats, suggesting that ferroptosis mediates the onset and development of IS and exacerbates cerebral injury ([@B1]; [@B23]; [@B39]).

Moreover, the inflammatory mechanism is probably responsible for the aggravation of cerebral ischemic injury mediated by ferroptosis. Typically, ferroptosis exerts a strong pro-inflammatory effect through the release of pro-inflammatory mediators, and this inflammatory response is the key mechanism of cerebral ischemic injury (for review, see [@B49]). Although research in this field is limited, a recent review indicated that ferroptosis plays an important role in inflammation ([@B65]) and, reportedly, inflammation is activated in ferroptotic tissues in mouse kidney injury models ([@B48]). Additionally, the relationship between inflammation and dead neurons was demonstrated in the GPX4-depleted model ([@B26]). Both the abovementioned findings provided an experimental basis for the hypothesis.

Potential Regulatory Mechanisms of Ferroptosis in Cerebral Ischemia {#S5}
===================================================================

The association between ferroptosis and cerebral ischemia is complex. Several previous studies elucidated that the activation of ferroptosis following an ischemic episode involves iron overload ([@B68]) and excitatory toxicity induced by the upregulation of xCT (one heterodimer composed of system xc-) ([@B6]), as well as lipid peroxidation mediated by the overexpression of ACSL4 ([@B24]) and 12/15-LOX ([@B75]; [Figure 1](#F1){ref-type="fig"}).

![Schematic representation of ferroptotic mechanisms following cerebral ischemia. This figure summarizes the potential mechanism of cerebral ischemia in regulating ferroptosis and the molecular mechanisms of ferroptosis: (i) the red arrows indicate that HIF-1α, DMT1, ACSL4, 12/15-LOX, system xc-, and IL-6 are upregulated by cerebral ischemia, which promotes ferroptosis and worsens cerebral ischemia injury; (ii) the blue arrows indicate that system xc- and GPX4 are repressed during cerebral ischemia, promoting ferroptosis and potentiating damage; (iii) the additional FSP1 pathway inhibits the formation of ROS through CoQ~10~H~2~, and the Nrf2 pathway represses ferroptosis by attenuating iron overload and oxidative damage; (iv) black arrows represent the molecular mechanisms of ferroptosis; and (v) green font indicates drugs that inhibit ferroptosis and interfere with ischemic brain injury. Blue arrows indicate inhibition, and red arrows indicate stimulation. HIF-1α, hypoxia-inducible factor 1-alpha; DMT1, divalent metal transporter 1; ASL4, acyl-CoA synthetase long-chain family member 4; IL-6, interleukin 6; glutathione peroxidase 4; LOX, lipoxygenase; ROS, reactive oxygen species; FSP1, ferroptosis suppressor protein 1; Nrf2, nuclear factor erythroid 2-related factor 2 (Nrf2).](fnins-14-00776-g001){#F1}

Mechanisms of Iron Overload During Cerebral Ischemia {#S5.SS1}
----------------------------------------------------

Iron overload following IS is profoundly significant upon the activation of ferroptosis. Reportedly, iron overload after cerebral ischemia aggravated cell death in brain tissues, whereas blockade of iron overload elicited the opposite effect, protecting cerebral tissues from ischemic injury ([@B68]).

Additionally, a study reported that serum levels of hepcidin and iron increased in IS patients. This indicates that hepcidin plays an important role in iron overload during cerebral ischemia ([@B54]). The internalization and degradation of hepcidin are induced through its binding with FPN1 on the cell membrane, rendering it a negative regulator of iron release ([@B54]). Currently, there are two potential pathways responsible for iron overload in ischemic brain tissue. The primary pathway involves increased expression of interleukin-6 (IL-6) owing to ischemia. IL-6 potentiates the expression of hepcidin through the JAK/STAT3 pathway, leading to a decrease in FPN1 and, consequently, reduced iron release. This results in intracellular iron overload ([@B12]). However, the mechanism of IL-6 upregulation in cerebral ischemia remains unclear. Similarly, the upregulation of hypoxia-inducible factor 1-alpha (HIF-1α) after cerebral ischemia results in iron overload, increasing transferrin receptor 1 (TFR1) expression. Considering that the TF-TFR1 pathway is potentially necessary for neurons to absorb iron, the increased iron uptake is possibly a decisive step for iron overload ([@B35]; [@B66]).

Moreover, inhibition of iron overload can reduce the damage caused by IS. In transient IS models, an intramuscular injection of the iron-chelating agent deferoxamine markedly reduces the volume of cerebral infarction ([@B70]). Another iron-chelating agent, 2,2-bipyridine, exerted a protective effect in a rat model of permanent cerebral ischemia ([@B11]). A specific iron-chelating agent, salicylaldehyde isonicotinoyl hydrazine (SIH), effectively alleviated ischemia--reperfusion injury ([@B68]). Therefore, iron overload occurs in IS and is closely related to ferroptosis, implying that iron overload is an important regulatory mechanism of ferroptosis in IS.

Iron-Related Proteins and IS {#S5.SS2}
----------------------------

Recent studies revealed that TFR1 expression is upregulated in the brain during cerebral ischemia in rats, and Naotaifang extract reduces TFR1 expression to inhibit ferroptosis and improve brain injury ([@B39]). Paradoxically, some studies demonstrated that TFR has the opposite effect. Pretreatment with low-dose thrombin can increase the HIF-1α level through the p44/42 MAPK pathway, upregulating TF and TFR expression in the brain parenchyma and reducing iron-overload-mediated cerebral ischemic injury ([@B30]). This is because the brain TF can absorb iron from the circulation, and, additionally, iron can also quickly flow from the brain into the bloodstream ([@B76]). This may suggest that the upregulation of TFR1 leads to iron overload, and accumulation of TFR1 beyond a certain threshold will allow iron clearance and reduce iron overload ([@B30]). Nevertheless, further investigations are imperative to elucidate the comprehensive effects of TFR1. Moreover, DMT1 expression was upregulated in rats with cerebral ischemia, and DMT1 inhibitors protected against ferroptosis, reducing cerebral ischemia injury ([@B39]).

Amino Acid Metabolism and Cerebral Ischemia {#S6}
===========================================

Expression of System xc- Is Upregulated in Cerebral Ischemia, Aggravating Injury {#S6.SS1}
--------------------------------------------------------------------------------

Notably, glutamate excitotoxicity after cerebral ischemia has been described as ferroptosis and can be effectively inhibited by the ferroptotic inhibitor ferrostatin-1 ([@B13]). Moreover, glutamate excitotoxicity has been proposed as a mechanism of ferroptosis ([@B38]). Signaling through glutamate receptors located on the neuronal cytomembrane, especially the N-methyl-D-aspartate receptor (NMDAR), promotes intracellular signaling and directly induces cell death ([@B6]). NMDAR promotes calcium influx, extracellular iron uptake (including free iron and holotransferrin), and neuronal excitotoxicity through the NMDA-NO-Dexras1-PAP7-DMT1 pathway ([@B6]).

System xc- is a heterodimer composed of SLC3A2 (regulatory subunit) and SLC7A11 (also known as xCT), playing a key role in the amino acid transport system ([@B13]). In most animal models of neurological diseases, xCT is upregulated and leads to the release of non-synaptic glutamate, which in turn activates glutamate receptors. Excitotoxicity induced by xCT through glutamate receptors circumvents the antioxidant protection afforded by system xc- itself ([@B44]). After the *in vitro* oxygen-glucose deprivation of neurons, HIF-1α binds to the promoter of xCT, upregulating its expression and then inducing injury ([@B29]). Conversely, the downregulation of xCT expression by N-acetylcysteine and ceftriaxone significantly reduced IS injury ([@B37]). Neuronal excitotoxicity, also called ferroptosis, damages ischemic tissue through NMDAR activation, mediated by an increased extracellular glutamate content, mainly caused xCT after cerebral ischemia; repression of system xc- can inhibit ferroptosis to prevent damage. However, deletion of the transport subunit of system xc- does not impair the development of a young mouse brain and exerts only a marginal impact on an adult mouse brain ([@B57]), possibly induced by the presence of a substance compensating for system xc- *in vivo*. This rationalizes that an increased expression of system xc- in cerebral ischemia cannot inhibit but can promote the occurrence of ferroptosis. Intriguingly, a study has demonstrated that increased expression of the *p53* gene in rats repressed xCT and resulted in ferroptosis during cerebral ischemia ([@B39]). These seemingly contradictory results suggest that there exists an intricate relationship between xCT, cerebral ischemia, and ferroptosis. Therefore, additional research in this direction is needed in the future.

Upregulation of GPX4 and GSH Can Improve Cerebral Ischemic Injury {#S6.SS2}
-----------------------------------------------------------------

GPX4 and GSH are endogenous inhibitors of ferroptosis, and their content is closely related to cerebral ischemia. Presently, it is believed that the loss of GPX4 function is crucial for ferroptosis owing to its pivotal role in the inhibition of lipid peroxidation ([@B63]). Furthermore, the inhibition of ferroptosis by GPX4 suppression reduced brain damage in rats subjected to ischemic damage. In ischemic rat models, significantly low levels of GPX4 resulted in ferroptosis, whereas high levels of GPX4 could improve brain injury ([@B39]). Selenium promotes the expression of GPX4 by activating the transcription factors TFAP2c and Sp1, effectively inhibiting ferroptosis, and alleviating IS injury ([@B1]). Carvacrol, a drug indicated for the treatment of cerebral ischemia, is beneficial in inhibiting ferroptosis in gerbils by potentiating the expression of GPX4 and attenuating hippocampal neuronal damage during cerebral ischemia--reperfusion injury ([@B23]).

GSH is essential for GPX4 activity; furthermore, it is the only intracellular ligand of Fe^2+^ that prevents the generation of highly toxic hydroxyl radicals, thereby inhibiting ferroptosis ([@B55]). Moreover, promoting GSH generation is beneficial for ameliorating IS. As a clinically approved drug for acute IS, edaravone has been proposed to combat ferroptosis, especially in cystine deficiency ([@B28]). In summary, enhanced GPX4 expression and GSH synthesis can suppress ferroptosis and mitigate ischemic brain damage. However, currently, researchers are focusing on the effect of GPX4 and GSH rather than on the upstream mechanism of cerebral ischemia.

Lipid Metabolism and Cerebral Ischemia {#S7}
======================================

Inhibition of ACSL4 Inhibits Ferroptosis and Improves Cerebral Ischemic Injury {#S7.SS1}
------------------------------------------------------------------------------

ACSL4 and LPCAT3 are involved in the remodeling of phosphatidylethanolamine, which affects the synthesis of lipid peroxides. However, only ACSL4 is upregulated and participates in ischemic injury. Reportedly, the inhibition of ACSL4 can prevent ferroptosis; thus, cell death and intestinal injury are alleviated ([@B47]). Additionally, ACSL4 is widely expressed in brain tissues and is increased during cerebral ischemia, with an increased expression of miRNA-347 upregulating ACSL4 at the post-transcriptional level, and mediating neuronal death ([@B24]). Rosiglitazone can selectively repress the activity of ACSL4, thereby preventing ferroptosis in the neurons of cerebral ischemic models and protecting brain function ([@B58]). In summary, the upregulation of ACSL4 after cerebral ischemia induces ferroptosis in neurons, leading to IS injury.

Inhibition of Lox Can Inhibit Ferroptosis and Improve Cerebral Ischemic Injury {#S7.SS2}
------------------------------------------------------------------------------

LOX is the key enzyme catalyzing PUFAs to initiate lipid peroxidation and ferroptosis ([@B42]), highly expressed after cerebral ischemia, and LOX inhibitors can suppress ferroptosis ([@B42]) to attenuate injury ([@B34]). One LOX inhibitor, called ML351, exerted a protective effect in cerebral ischemia--reperfusion injury ([@B68]). Furthermore, there are several subtypes of LOX, including 12/15-LOX. In animal models of brain ischemia, 12/15-LOX expression increases, and the inhibition of 12/15-LOX can reduce the rate of the neuronal death, improving recovery ([@B34]). Previous studies have shown that suppressing 12/15-LOX can result in the inhibition of ferroptosis ([@B46]). To date, it remains unclear whether multiple subtypes work in conjunction or whether only one subtype is sufficient to initiate lipid peroxidation and ferroptosis, necessitating further study.

In conclusion, the mechanism of ferroptosis during cerebral ischemia is related to the accumulation of intracellular Fe^2+^, lipid peroxides, and oxidative damage induced by the downregulation of GPX4. The specific factors are as follows: the increased expression of HIF-1α enhances the expression of TFR1 and xCT, both of which potentiate iron uptake and iron overload; increased IL-6 induces an increase in hepcidin content, which suppresses iron excretion and leads to iron overload; an unknown mechanism triggers the downregulation of GPX4; and increased expression of ACSL4 and 12/15-LOX leads to lipid peroxidation in the cell membrane.

Other Mechanisms: Inhibition of Ferroptosis by Nrf2 Is Expected to Improve Is Injury {#S8}
====================================================================================

Nuclear factor erythroid-2-related factor 2 (Nrf2) is an important regulator of the cellular antioxidant defense system. A study demonstrated that the appropriate activation of Nrf2 promotes the alleviation of cerebral ischemic injury ([@B50]). Several genes targeted by Nrf2 are strongly associated with the progression of ferroptosis, including ferritin heavy chain 1, FPN1, GSH, and GPX4 ([@B50]; [@B36]). Furthermore, it has been clarified that the expression level of Nrf2 is dependent on ferroptosis sensitivity. The enhanced expression of Nrf2 can inhibit ferroptosis. Conversely, the inhibition of Nrf2 expression induces ferroptosis ([@B64]). Nrf2 inhibits ferroptosis by promoting the expression of GSH and GPX4, thus enhancing antioxidant function. Moreover, Nrf2 promotes the expression of ferritin and FPN1 to store and secrete free iron concurrently, thus reducing the accumulation of iron in cells and preventing ferroptosis ([@B74]). Therefore, Nrf2 is a promising anti-ferroptosis target.

Currently, evidence clarifying the mechanism by which Nrf2 directly affects ferroptosis during stroke is scarce. However, there are several indications regarding the role of the Nrf2 pathway in IS. Reportedly, epicatechin can cross the blood--brain barrier to exert a protective effect in transient IS through the Nrf2 pathway ([@B59]). However, related laboratory and clinical data elucidating this mechanism remain lacking.

Concluding Remarks and Perspectives {#S9}
===================================

Cerebral ischemia can induce ferroptosis and, in turn, ferroptosis aggravates cerebral ischemic injury; inhibiting ferroptosis can alleviate this injury. However, the regulatory mechanisms involved with ferroptosis in cerebral ischemia, including iron overload and regulatory mechanisms upstream of GPX4, 12/15-LOX, and Nrf2, remain unclear; in particular, whether ferroptosis causes cell death directly or by other means requires further investigation. Additionally, the relationship between ferroptosis and other cell death mechanisms, such as apoptosis and pyroptosis, in cerebral ischemia, is an important direction for future research. The resolution of these obstacles will provide crucial support for the development of ferroptosis as a target in cerebral ischemia interventions and an important direction for the study of pathological mechanisms involved in cerebral ischemia.
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